Novavax to Report First Quarter 2025 Financial Results on May 8, 2025
Rhea-AI Summary
Novavax (NASDAQ: NVAX) has scheduled its first quarter 2025 financial results and operational highlights conference call for May 8, 2025, at 8:30 a.m. Eastern Time. Participants can join through phone registration or direct dial-in, with connection recommended 10 minutes before the start time.
A replay of the conference call will be available from 11:30 a.m. ET on May 8 until 11:59 p.m. ET on May 15, 2025. The webcast replay will remain accessible through June 7, 2025, on the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – NVAX
In the trading session that priced this news, NVAX declined 3.90%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call details: | |
Date: | May 8, 2025 |
Time: | 8:30 a.m. |
URL to register phone: | |
Dial-in number: | (800) 836-8184 (Domestic) or |
(+1) (646) 357-8785 (International) | |
Webcast: |
- Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.
Replay details: | |
Date: | Available starting at 11:30 a.m. |
Dial-in number: | (888) 660-6345 (Domestic) or |
(+1) (646) 517-4150 (International) | |
Passcode: | 88407# |
Webcast: | ir.novavax.com/events, until June 7, 2025 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines and its cutting-edge technology platform, which includes protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy is focused on building new and diversified partnerships via the out-licensing of its technology platform and vaccine assets earlier in the development process. These strategic collaborations are fueled by smart investments in a growing early-stage pipeline starting with the Company's core expertise in infectious disease and potentially expanding into other disease areas. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Giovanna Chandler
202-709-5563
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-report-first-quarter-2025-financial-results-on-may-8-2025-302443439.html
SOURCE Novavax, Inc.